This review provides an overview of the current insights into the role of PCSK9 in cholesterol metabolism and cancer biology and discuss the potential benefits and challenges of combining PCSK9 inhibition with anti-PD-1/PD-L1 immunotherapy for cancer treatment. The gene discussed is PDCD1; the disease is cancer.